Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

BACKGROUND: Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease. Studies of atherothrombotic treatments in this population have been disappointing to date. Icosapent ethyl reduced the risk of atherosclerotic cardiovascular disease among a broad array of stati...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvaraj, Senthil, Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Juliano, Rebecca A., Jiao, Lixia, Tardif, Jean‐Claude, Ballantyne, Christie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075460/
https://www.ncbi.nlm.nih.gov/pubmed/35377160
http://dx.doi.org/10.1161/JAHA.121.024999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075460/
https://www.ncbi.nlm.nih.gov/pubmed/35377160
http://dx.doi.org/10.1161/JAHA.121.024999

Ejemplares similares